Compare EZPW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZPW | TSHA |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1996 | 2020 |
| Metric | EZPW | TSHA |
|---|---|---|
| Price | $32.62 | $6.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $30.67 | $11.63 |
| AVG Volume (30 Days) | 1.0M | ★ 2.6M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.09 | 5.56 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $747,954,000.00 | $9,773,000.00 |
| Revenue This Year | $25.40 | N/A |
| Revenue Next Year | $11.33 | $1,152.42 |
| P/E Ratio | $17.43 | ★ N/A |
| Revenue Growth | 2.39 | ★ 17.28 |
| 52 Week Low | $15.96 | $2.72 |
| 52 Week High | $37.13 | $7.30 |
| Indicator | EZPW | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 48.49 |
| Support Level | $30.94 | $5.28 |
| Resistance Level | $36.88 | $6.88 |
| Average True Range (ATR) | 1.50 | 0.34 |
| MACD | 0.36 | -0.01 |
| Stochastic Oscillator | 89.58 | 31.82 |
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.